These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 12813173)
1. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. Kumagai T; O'Kelly J; Said JW; Koeffler HP J Natl Cancer Inst; 2003 Jun; 95(12):896-905. PubMed ID: 12813173 [TBL] [Abstract][Full Text] [Related]
2. 19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines. Molnár I; Kute T; Willingham MC; Powell BL; Dodge WH; Schwartz GG J Cancer Res Clin Oncol; 2003 Jan; 129(1):35-42. PubMed ID: 12618899 [TBL] [Abstract][Full Text] [Related]
3. Suppressive effect of 19-nor-1α-25-dihydroxyvitamin D2 on gastric cancer cells and peritoneal metastasis model. Park MR; Lee JH; Park MS; Hwang JE; Shim HJ; Cho SH; Chung IJ; Bae WK J Korean Med Sci; 2012 Sep; 27(9):1037-43. PubMed ID: 22969249 [TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells. Alagbala AA; Johnson CS; Trump DL; Posner GH; Foster BA Oncology; 2006; 70(6):483-92. PubMed ID: 17237623 [TBL] [Abstract][Full Text] [Related]
6. Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model. Nachliely M; Trachtenberg A; Khalfin B; Nalbandyan K; Cohen-Lahav M; Yasuda K; Sakaki T; Kutner A; Danilenko M J Steroid Biochem Mol Biol; 2019 Apr; 188():8-16. PubMed ID: 30508646 [TBL] [Abstract][Full Text] [Related]
7. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Kumagai T; Shih LY; Hughes SV; Desmond JC; O'Kelly J; Hewison M; Koeffler HP Cancer Res; 2005 Mar; 65(6):2488-97. PubMed ID: 15781666 [TBL] [Abstract][Full Text] [Related]
8. 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Schwartz GG; Eads D; Naczki C; Northrup S; Chen T; Koumenis C Cancer Biol Ther; 2008 Mar; 7(3):430-6. PubMed ID: 18094617 [TBL] [Abstract][Full Text] [Related]
9. Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids. Halder SK; Sharan C; Al-Hendy O; Al-Hendy A Reprod Sci; 2014 Sep; 21(9):1108-19. PubMed ID: 24925855 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model. Moore RG; Lange TS; Robinson K; Kim KK; Uzun A; Horan TC; Kawar N; Yano N; Chu SR; Mao Q; Brard L; DePaepe ME; Padbury JF; Arnold LA; Brodsky A; Shen TL; Singh RK PLoS One; 2012; 7(4):e34443. PubMed ID: 22509304 [TBL] [Abstract][Full Text] [Related]
11. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102 [TBL] [Abstract][Full Text] [Related]
12. 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors. Zinser GM; Tribble E; Valrance M; Urben CM; Knutson JC; Mazess RB; Strugnell SA; Welsh J Anticancer Res; 2005; 25(1A):235-41. PubMed ID: 15816543 [TBL] [Abstract][Full Text] [Related]
13. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Sochorová K; Budinský V; Rozková D; Tobiasová Z; Dusilová-Sulková S; Spísek R; Bartůnková J Clin Immunol; 2009 Oct; 133(1):69-77. PubMed ID: 19660988 [TBL] [Abstract][Full Text] [Related]
14. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Zinser GM; McEleney K; Welsh J Mol Cell Endocrinol; 2003 Feb; 200(1-2):67-80. PubMed ID: 12644300 [TBL] [Abstract][Full Text] [Related]
15. The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression. Shany S; Levy Y; Lahav-Cohen M Steroids; 2001; 66(3-5):319-25. PubMed ID: 11179740 [TBL] [Abstract][Full Text] [Related]
16. Novel analogs of 1,25-dihydroxyvitamin D Nachliely M; Sharony E; Kutner A; Danilenko M J Steroid Biochem Mol Biol; 2016 Nov; 164():59-65. PubMed ID: 26365556 [TBL] [Abstract][Full Text] [Related]
17. Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Park WH; Seol JG; Kim ES; Jung CW; Lee CC; Binderup L; Koeffler HP; Kim BK; Lee YY Exp Cell Res; 2000 Feb; 254(2):279-86. PubMed ID: 10640426 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines. Brard L; Lange TS; Robison K; Kim KK; Ara T; McCallum MM; Arnold LA; Moore RG; Singh RK Gynecol Oncol; 2011 Nov; 123(2):370-8. PubMed ID: 21803404 [TBL] [Abstract][Full Text] [Related]
19. Activation of vitamin D receptor attenuates high glucose-induced cellular injury partially dependent on CYP2J5 in murine renal tubule epithelial cell. Liu Y; Li L; Yi B; Hu ZX; Li AM; Yang C; Zheng L; Zhang H Life Sci; 2019 Oct; 234():116755. PubMed ID: 31415769 [TBL] [Abstract][Full Text] [Related]
20. Biological evaluation of new vitamin D Corcoran A; Bermudez MA; Seoane S; Perez-Fernandez R; Krupa M; Pietraszek A; Chodyński M; Kutner A; Brown G; Marcinkowska E J Steroid Biochem Mol Biol; 2016 Nov; 164():66-71. PubMed ID: 26429396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]